EcoDrugPlus

40s Ribosomal Protein S16-Like

Ensembl ID : ENSPKIG00000004000
Gene Symbol: LOC111857610
3 Cross references
311 Possible Orthologues:

40s Ribosomal Protein S26

Ensembl ID : ENSPKIG00000025224
Gene Symbol: LOC111860617
2 Cross references
416 Possible Orthologues:

40s Ribosomal Protein S3a

Ensembl ID : ENSPKIG00000014006
Gene Symbol: LOC111852108
4 Cross references
359 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSPKIG00000017479
Gene Symbol: NT5E
3 Cross references
250 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSPKIG00000020198
Gene Symbol: HTR1B
2 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSPKIG00000017458
Gene Symbol: HTR1B
1 Cross references
184 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSPKIG00000017632
Gene Symbol: HTR1E
2 Cross references
65 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSPKIG00000020003
Gene Symbol: HTR2A
3 Cross references
219 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSPKIG00000020223
Gene Symbol: LOC111836399
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSPKIG00000002239
Gene Symbol: HTR2B
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSPKIG00000005685
Gene Symbol: HTR2B
3 Cross references
135 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSPKIG00000001268
Gene Symbol: LOC111856908
2 Cross references
155 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).